Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/a-2182-5365
Psychopharmakotherapie mit dem MAO-Hemmer Tranylcypromin Schwerpunkte und Trends aus Theorie und Praxis
Psychopharmacotherapy with the MAO-inhibitor Tranylcypromine Key Aspects and Trends in Theory and Practice![](https://www.thieme-connect.de/media/fdn/EFirst/lookinside/thumbnails/0555-12-2022_10-1055-a-2182-5365-1.jpg)
Zusammenfassung
Der irreversible Monoaminoxidase-Hemmer Tranylcypromin ist seit mehr als 60 Jahren als Antidepressivum bekannt. Ziel dieses Übersichtsartikels ist die Bestimmung des Standes der Wissenschaft und Therapie von Tranylcypromin. Dafür wird die aktuelle Fachliteratur ausgewertet und hinsichtlich gegenwärtiger Schwerpunkte und allgemeiner Trends der praktischen Psychopharmakotherapie eingeordnet. Im Ergebnis kann Tranylcypromin heute durch neue Metaanalysen kontrollierter Studien als gut etabliert für die Behandlung der therapieresistenten Depression gelten. Die Dosierung (Maximaldosis, Erhaltungsdosis) wird zunehmend für Anforderungen der therapieresistenten Depression angepasst. Die Monoaminoxidase ist nicht nur primäre pharmakologische Zielstruktur von Tranylcypromin sondern bestimmt zu Therapiebeginn als arzneistoffmetabolisierendes Enzym enantioselektiv auch die Pharmakokinetik des Monoaminoxidase-Hemmers. Mit zunehmender Diversität der antidepressiven Pharmakotherapie ist eine fortwährende Zuordnung von Tranylcypromin als therapeutische „ultima ratio“ bei Depression überdenkenswert. Es wird geschlussfolgert, dass Tranylcypromin als Mittel der zweiten Wahl eine wertvolle Option der antidepressiven Therapie bleibt. Die Kriterien für eine Umstellung von anderen Antidepressiva auf den Monoaminoxidase-Hemmer müssen noch besser definiert werden.
Abstract
The irreversible monoamine oxidase inhibitor tranylcypromine has been known as an antidepressant drug for more than 60 years. The aim of this review was to make an assessment of the state of the art and therapy of tranylcypromine. The recent medical-scientific literature is analyzed and discussed with respect to key aspects of and general trends in practical psychopharmacotherapy. Meta-analyses of controlled clinical studies have shown that tranylcypromine is an established approach to treatment-resistant depression. Doses (maximum dose, maintenance dose) are increasingly adapted to the requirements of treatment-resistant depression. Monoamine oxidase is not only the primary pharmacological target of tranylcypromine but determines for the first doses also the pharmacokinetics of tranylcypromine because monoamine oxidase is also an enantioselective drug-metabolizing enzyme of the monoamine oxidase inhibitor. An increased diversity of the antidepressant pharmacotherapy suggests the need to rethink the continuing assessment of tranylcypromine as a therapeutic “ultima ratio” in depression. In conclusion, tranylcypromine as a drug of second choice remains a valuable option in antidepressant treatment. Criteria of a switch from other antidepressant drugs to tranylcypromine should be better defined.
Publication History
Received: 30 December 2022
Accepted: 17 August 2023
Article published online:
21 November 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart,
Germany
-
Literatur
- 1 Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacol 1995; 12: 185-219
- 2 Ulrich S, Ricken R, Adli M. Tranylcypromine in mind (Part I): Review of pharmacology. Eur Neuropsychopharmacol 2017; 27: 697-713
- 3 Van den Eynde V, Abdelmoemin WR, Abraham MM. et al. The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression. CNS Spectr 2022; 15: 1-14
- 4 Ulrich S, Hock D, Guth V. et al. Insufficient recovery of monoamine oxidase in a bioequivalence study of the monoamine oxidase inhibitor tranylcypromine: Recommendation of the tranylcypromine enantiomer test. Int J Clin Pharmacol Ther 2022; 60: 242-252
- 5 Moriguchi S, Wilson AA, Miler L. et al. Monoamine oxidase B total distribution volume in the prefrontal cortex of major depressive disorder: An [11C]-SL25.1188 PET study. JAMA Psychiat 2019; 76: 634-641
- 6 Lewitzka U, Müller-Oerlinghausen B, Felber W. et al. Is MAO-B activity in platelets associated with the occurrence of suicidality and behavioural personality traits in depressed patients?. Acta Psychiatr Scand 2008; 117: 41-49
- 7 Hampson DR, Baker GB, Coutts RT. Neurochemical changes in rat brain amines after short- and long-term inhibition of monoamine oxidase by a low dose of tranylcypromine. Biol Psychiat 1988; 23: 227-236
- 8 Greenshaw AJ, Rao TS, Nazarali AJ. et al. Chronic effects of tranylcypromine and 4-fluorotranylcypromine on regional brain monoamine metabolism in rats: A comparison with clorgyline. Biol Psychiat 1989; 25: 1014-1020
- 9 Chung MY, Kim DG, Yoo KJ. et al. Regional differences in the levels of biogenic amines and their metabolites in rat brain after tricyclic antidepressant treatments. Yonsei Med J 1993; 34: 266-277
- 10 Da Prada M, Kettler R, Keller HH. et al. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 1989; 248: 400-414
- 11 Haleem DJ, Haider S, Yasmeen A. et al. The neurochemical profile of long term oral administration of moclobemide. Pak J Pharm Sci 1998; 11: 9-14
- 12 Hyttel J. Neurochemical characterization of a new potent and selective serotonin uptake inhibitor: Lu 10-171. Psychopharmacology (Berl) 1977; 51: 225-233
- 13 Ricken R, Ulrich S, Schlattmann P. et al. Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression. Eur Neuropsychopharmacol 2017; 27: 714-731
- 14 Verspohl EJ. Antidepressiva. In: Ammon HPT, Hrsg. Arzneimittelneben- und -wechselwirkungen. Stuttgart: WVG; 1991: 281-316
- 15 Nestler EJ, McMahon A, Sabban EL. et al. Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus. Proc Natl Acad Sci USA 1990; 87: 7522-7526
- 16 Tomaz VS, Chaves Filho AJM, Cordeiro RC. et al. Antidepressants of different classes cause distinct behavioral and brain pro- and anti-inflammatory changes in mice submitted to an inflammatory model of depression. J Affect Disord 2020; 268: 188-200
- 17 Maki Y, Inoue T, Izumi T. et al. Monoamine oxidase inhibitors reduce conditioned fear stress-induced freezing behavior in rats. Eur J Pharmacol 2000; 406: 411-418
- 18 Ulrich S, Ricken R, Schlattmann P. et al. Metaanalyse kontrollierter Studien von Tranylcypromin bei Depression und Bewertung der Qualität des Studiendesigns. Psychopharmakother 2017; 24: 259-271
- 19 Nolen WA, van den Broek WW, Birkenhäger TK. Treatment with low doses of tranylcypromine resulted in a disappointing remission rate. Am J Psychiat 2007; 164: 524
- 20 Möller HJ. Das Problem der Heterogenität zwischen in den USA und nicht in den USA durchgeführten Antidepressivastudien. Psychopharmakother 2014; 21: 211-218
- 21 Anghelescu IG. Einsatz von Antidepressiva bei therapieresistenten Depressionen. In: Bauer M, Berghöfer A, Brakemeier EL, Adli M, Hrsg. Therapieresistenz bei Depressionen und bipolaren Störungen. Berlin: Springer; 2022: 105-119
- 22 Volz HP, Ugur T. Antidepressiva. In: Kasper S, Volz HP, Hrsg. Psychiatrie und Psychotherapie compact: Das gesamte Facharztwissen. Stuttgart: Thieme; 2008: 299-325
- 23 Ulrich S, Ricken R, Buspavanich P. et al. Efficacy and adverse effects of tranylcypromine and tricyclic antidepressants in the treatment of depression: A systematic review and comprehensive meta-analysis. J Clin Psychopharmacol 2020; 40: 63-74
- 24 Langner E. Die Behandlung psychotischer Antriebstörungen. Wien Med Wochenschr 1968; 118: 700-702
- 25 Roesch-Ely D, Speck L, Ulrich S. et al. Adjuvantes Tranylcypromin mit Antipsychotika der zweiten Generation in der Behandlung schizophrener Negativsymptomatik: Retrospektive Studie zur Therapieroutine von 53 Patienten und Kurzübersicht zur Literatur. Psychopharmakother 2011; 18: 66-74
- 26 Ulrich S, Messer T. Review and meta-analysis of add-on tranylcypromine with antipsychotic drugs for the treatment of schizophrenia with predominant negative symptoms: A restoration of evidence. Curr Med Res Opin 2021; 37: 1233-1248
- 27 Heijnen WT, De Fruyt J, Wierdsma AI. et al. Efficacy of tranylcypromine in bipolar depression: A systematic review. J Clin Psychopharmacol 2015; 35: 700-705
- 28 Mallinger AG, Frank E, Thase ME. et al. Revisiting the effectiveness of standard antidepressants in bipolar disorder: Are monoamine oxidase inhibitors superior?. Psychopharmacol Bull 2009; 42: 64-74
- 29 Parker G, Malhi GS, Hamilton A. et al. Stepwise treatment of acute bipolar depression. Bipolar Disord 2019; 21: 465-469
- 30 Faria CGF, Fidry M, Costa do Cabo M. A Brazilian case of treatment-resistant generalized anxiety disorder successfully treated with monoamine oxidase inhibitor (MAOI). Psychiatr Danub 2020; 32: 139-141
- 31 Börner RF, Lühring F. Tranylcypromin bei chronifizierter therapieresistenter Agoraphobie mit Panikstörung und rezidivierender depressiver Störung. Psych Prax 2010; 37: 350-352
- 32 Versiani M, Mundim FD, Nardi AE. et al. Tranylcypromine in social phobia. J Clin Psychopharmacol 1988; 8: 279-283
- 33 Picardi A, Panchero P. Differential response to antidepressant drugs in outpatients affected by anxiety or depressive disorders and scoring high on the scales 1 and 3 of the MMPI-2. Riv Psich 1997; 32: 241-250
- 34 Nardi AE, Lopes FL, Valença AM. et al. Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder. Psychiatry Res 2010; 175: 260-265
- 35 Winkelman NW. Three evaluations of monoamine oxidase inhibitor and phenothiazine combination. Dis Nerv Syst 1965; 26: 160-164
- 36 Erfurth A, Schmauss M. Monoaminoxidase-Hemmer in der Behandlung von Zwangserkrankungen. Nervenarzt 1993; 64: 70-72
- 37 Riederer P, Laux G. MAO-inhibitors in Parkinson’s disease. Exp Neurobiol 2011; 20: 1-17
- 38 Barbeau A, Duchastel Y. Tranylcypromine and the extrapyramidal syndromes. Can Psychiatr Assoc J 1962; 7: 91-5
- 39 Reynolds GP, Riederer P, Sandler M. Tranylcypromine isomers and Parkinson̛s disease: New aspects of an old drug. J R Soc Med 1981; 74: 649-652
- 40 Laux G. Antidepressiva-Therapie bei Morbus Parkinson. Psychopharmakother 2022; 29: 49-55
- 41 Adli M, Pilhatsch M, Bauer M. et al. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression. Pharmacopsychiat 2008; 41: 252-257
- 42 Ferreira-Garcia R, da Rocha Freire RC, Appolinário JC. et al. Tranylcypromine plus amitriptyline for electroconvulsive therapy-resistant depression: A long-term study. J Clin Psychopharmacol 2018; 38: 502-504
- 43 Kim T, Xu C, Amsterdam JD. Relative effectiveness of tricyclic antidepressant versus monoamine oxidase inhibitor monotherapy for treatment-resistant depression. J Affect Disord 2019; 250: 199-203
- 44 Ludwig VM, Sauer C, Young AH. et al. Cardiovascular effects of combining subcutaneous or intravenous esketamine and the MAO inhibitor tranylcypromine for the treatment of depression: A retrospective cohort study. CNS Drugs 2021; 35: 881-892
- 45 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Unipolare Depression – Langfassung, Version 3.0. 2022. Im Internet https://www.leitlinien.de/themen/depression Stand: 21.12.2022
- 46 Bönner G. Der hypertensive Notfall. Dtsch Med Wochenschr 2017; 142: 1437-1445
- 47 Schmidt LG, Grohmann R, Rüther E. Unerwünschte Wirkungen von Antidepressiva in der Routinebehandlung. Psychopharmakother 1994; 1: 6-15
- 48 Gillman PK. A reassessment of the safety profile of monoamine oxidase inhibitors: Elucidating tired old tyramine myths. J Neural Transm (Vienna) 2018; 125: 1707-1717
- 49 Van den Eynde V, Gillman PK, Blackwell BB. The prescriber’s guide to the MAOI diet – thinking through tyramine troubles. Psychopharmacol Bull 2022; 52: 73-116
- 50 Fritze J. Verordnung von Neuro-Psychopharmaka. Psychopharmakother 2023; 30: 96-99
- 51 Chamberlain SR, Baldwin DS. Monoamine oxidase inhibitors (MAOIs) in psychiatric practice: How to use them safely and effectively. CNS Drugs 2021; 35: 703-716
- 52 Shulman KI, Herrmann N, Walker SE. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs 2013; 27: 798-797
- 53 Suchting R, Tirumalajaru V, Gareeb R. et al. Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: A systematic review and network meta-analysis. J Affect Disord 2021; 282: 1153-1160
- 54 Wagner E, Seemüller F, Hasan A. 60 Years of combining tranylcypromine: A systematic review of available evidence. J Clin Psychopharmacol 2022; 42: 51-70
- 55 Thomas SJ, Shin M, McInnis MG. et al. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: Strategies for the management of treatment-resistant depression. Pharmacother 2015; 35: 433-449
- 56 Bodkin JA, Dunlop BW. Moving on with monoamine oxidase inhibitors. Focus (Am Psychiatr Publ) 2021; 19: 50-52
- 57 Hiemke C, Bergemann N, Clement HW. et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiat 2018; 51: 9-62
- 58 Kavakbasi E, Baune BT. Combination of tranylcypromine and mirtazapine in difficult-to-treat depression. J Clin Psychopharmacol 2021; 41: 585-588
- 59 Amsterdam JD, Kim TT. Relative effectiveness of monoamine oxidase inhibitor and tricyclic antidepressant combination therapy for treatment-resistant depression. J Clin Psychopharmacol 2019; 39: 649-652
- 60 Van Hunsel F, Zweers P. Gelijktijdig gebruik van tranylcypromine en trazodon kann leiden tot het serotoninesyndroom. Pharm Weekbl Wetenschappelijk Platform 2013; 7: a1326
- 61 Baker GB, Urichuk LJ, McKenna KF. et al. Metabolism of monoamine oxidase inhibitors. Cell Mol Neurobiol 1999; 19: 411-426
- 62 Thébault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: A potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacother 2004; 24: 1295-1305
- 63 Heinze G, Rossel L, Gabelic I. et al. Double-blind comparison of moclobemide and tranylcypromine in depression. Pharmacopsychiat 1993; 26: 240-245
- 64 Wang LuLJ, Domino E. Effects of iproniazid and tranylcypromine on the half-life of N,N-dimethyltryptamine in rat brain and liver. Biochem Pharmacol 1976; 25: 1521-1527
- 65 MacCallum CA, Lo LA, Pistawka CA. et al. Therapeutic use of psilocybin: Practical considerations for dosing and administration. Front Psychiat 2022; 13: 1040217
- 66 Gillman PK, Feinberg SS, Fochtmann LJ. Revitalizing monoamine oxidase inhibitors: A call for action. CNS Spectrums 2020; 25: 452-454
- 67 Ulrich S, Dimboiu A, Messer T. et al. Behandlung therapieresistenter Depression nach Non-Response auf Tranylcypromin. Psychopharmakother 2019; 26: 24-38